The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Pediatric HIV Infection: Drug Development for Treatment.'' This guidance provides general recommendations on the development of drug products for the treatment of human immunodeficiency virus (HIV) infection in pediatric patients (birth to younger than 17 years of age).
Document
Pediatric HIV Infection: Drug Development for Treatment; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Pediatric HIV Infection: Drug Development for Treatme...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 22270
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Pediatric HIV Infection: Drug Development for Treatment; Draft Guidance for Industry; Availability,” thefederalregister.org (May 14, 2018), https://thefederalregister.org/documents/2018-10187/pediatric-hiv-infection-drug-development-for-treatment-draft-guidance-for-industry-availability.